kite-363
Cell therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 27, 2021 (NCT04989803)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07304154 | Phase 1 | Jan 31, 2026 | Gilead Sciences |
| NCT07038447 | Phase 1 | Jul 2, 2025 | Gilead Sciences |
| NCT04989803 | Phase 1 | Oct 27, 2021 | Gilead Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1